Mirum Pharmaceuticals

@mirumpharma

Mirum is creating transformative medicine for children with rare cholestatic liver disease.

Vrijeme pridruživanja: siječanj 2019.

Tweetovi

Blokirali ste korisnika/cu @mirumpharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mirumpharma

  1. In celebration of on February 29, throughout the month we’ll share different facts about the rare diseases in which we’re working here at Mirum.

    Poništi
  2. 5. velj

    In honor of , we remember French pediatric hepatologist Daniel Alagille who first observed Alagille syndrome () in children in 1969 and published foundational work in The Journal of Pediatrics in 1975.

    Poništi
  3. 2. velj

    It’s Super Bowl Sunday and as we root for the teams playing this weekend, we at Mirum Pharma are always rooting for our young warriors battling Alagille syndrome () and progressive familial intrahepatic cholestasis ().

    Poništi
  4. 30. sij

    Mirum is driven to create transformative medicine for children with rare cholestatic liver diseases. Our growing team brings a history of expertise, and we are passionate about the patient population. We’re in multiple areas. Apply today:

    Poništi
  5. 28. sij

    Cedar was diagnosed with when she was five months old while traveling with her family. While individual diagnoses seldom look the same, the effects of the condition can be devastating on many levels. Click here to learn more:

    Poništi
  6. 25. sij

    Happy International Alagille Syndrome Awareness Day from Mirum Pharmaceuticals! We are proud supporters of the Alagille syndrome community. Join us in being !

    Poništi
  7. proslijedio/la je Tweet
    24. sij

    Team CanaleComm showing our support for & one of our clients, , on - we’re , are you?

    Poništi
  8. 24. sij
    Poništi
  9. proslijedio/la je Tweet
    24. sij

    Today is the day!! It’s International Day! Hear the family voice, learn about the disease, find resources and be on the Awareness Day page! Learn, support, share!

    Poništi
  10. 24. sij

    Today is the first-ever International ! As a patient-first organization, hear directly from Mirum Pharmaceuticals CEO Chris Peetz on the importance of this day.

    Poništi
  11. proslijedio/la je Tweet
    21. sij

    – Pruritus experienced by patients with is among the most severe in any chronic liver disease and Intractable pruritus can be severe enough to be an indication for liver transplantation.

    Poništi
  12. proslijedio/la je Tweet
    18. sij

    – The first ever International is on January 24! Join us in raising awareness for , celebrate our ALGS families and increase knowledge of this disease. Stand with us and be

    Poništi
  13. 22. sij

    Trey was nine years old when he was diagnosed with progressive familial intrahepatic cholestasis (). Learn more about his story:

    Poništi
  14. 16. sij

    Reminder: Mirum’s Phase 3 MARCH clinical study with maralixibat, an investigational medicine being evaluated in pediatric patients diagnosed with , is currently enrolling. Check to learn more today:

    Poništi
  15. 14. sij

    Are you a writer interested in advancing in your career alongside a team dedicated to improving the lives of children with rare liver conditions? We’re for multiple positions, including a Director, Medical Writing. Apply today:

    Poništi
  16. 14. sij

    We are thrilled to announce the well-deserved promotion of Ian Clements to Chief Financial Officer. Ian’s continued dedication and passion have been instrumental in our recent milestones and we look forward to our year ahead with him in his new position.

    Poništi
  17. proslijedio/la je Tweet
    14. sij

    - , CFO of , gives us a lookahead for Mirum in 2020

    Poništi
  18. 13. sij
    Poništi
  19. proslijedio/la je Tweet
    10. sij

    "The Foundation had a productive 2019 creating opportunities in research and education for and our affiliate organizations" NASPGHAN Foundation President Barry Wershil, MD highlights recent Foundation news in the NASPGHAN Winter Newsletter:

    Poništi
  20. 10. sij

    Have you listened to Mirum Pharmaceuticals CEO Chris Peetz share the team’s approach with the FDA to potentially accelerate maralixibat’s path to patients with Alagille syndrome? Hear more in the recent Endpoints webinar:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·